| M-701 |
M-701 |
Phase 3 Clinical |
Wuhan Yzy Biopharma Co Ltd |
Ovarian Neoplasms; Solid tumours; Hydrothorax; Stomach Neoplasms; Neoplasms; Ascites; Colorectal Neoplasms; Pleural Effusion, Malignant; Carcinoma, Non-Small-Cell Lung |
Details
|
| ABBV-383 |
TNB-383B; ABBV-383 |
Phase 3 Clinical |
Teneobio Inc, Abbvie Inc |
Multiple Myeloma |
Details
|
| IMC-F106C |
IMC-F106C; PRAME HLA-A02 |
Phase 3 Clinical |
Immunocore Ltd |
Solid tumours; Melanoma |
Details
|
| Alnuctamab |
CC-93269; EM-901; BMS-986349 |
Phase 3 Clinical |
Engmab Ag |
Multiple Myeloma |
Details
|
| Catumaxomab |
LP000 |
Phase 3 Clinical |
Trion Research, Neovii Biotech Gmbh |
Ovarian Neoplasms; Stomach Neoplasms; Carcinoma; Neoplasms; Carcinoma, Ovarian Epithelial; Colonic Neoplasms; Urinary Bladder Neoplasms; Ascites; Breast Neoplasms |
Details
|
| Flotetuzumab |
S-80880; MGD-006; RES-234 |
Phase 2 Clinical |
Macrogenics Inc |
Leukemia, Myelogenous, Chronic; Hematologic Neoplasms; Leukemia; Leukemia, Hairy Cell; Mastocytosis, Systemic; Hodgkin Disease; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Neoplasms, Plasma Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Leukemia, Myeloid, Acute; Leukemia, Biphenotypic, Acute |
Details
|
| Anti-CD3/humanized 3F8 bispecific antibody-activated T lymphocytes (University of Virginia) |
|
Phase 2 Clinical |
University Of Virginia |
Neuroblastoma |
Details
|
| Imvotamab |
IGM-2323 |
Phase 2 Clinical |
Igm Biosciences Inc |
Lymphoma, B-Cell, Marginal Zone; Myositis; Lupus Erythematosus, Cutaneous; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Lupus Erythematosus, Systemic; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Arthritis; Lymphoma, Non-Hodgkin |
Details
|
| Foralumab |
TZLS-401; NI-0401/α-CD3; NI-0401 |
Phase 2 Clinical |
Novimmune Sa, Bristol-Myers Squibb Company |
Respiratory Tract Infections; Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Coronavirus Disease 2019 (COVID-19); Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis; Alzheimer Disease; Crohn Disease |
Details
|
| GNR-084 |
GNR-084 |
Phase 2 Clinical |
Generium Pharmaceuticals, Iontas |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| Anti-CD3 and anti-HER2 BiTE-expressing T cell (MedImmune) |
|
Phase 2 Clinical |
University Of Michigan, Huazhong University Of Science And Technology, University Of Virginia Cancer Center, Medimmune |
Breast Neoplasms |
Details
|
| Vibecotamab |
XmAb-14045 |
Phase 2 Clinical |
Xencor Inc |
Leukemia, Myeloid; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute |
Details
|
| α/β CD3+/CD19+ cell depleted stem cell therapy (Mitchell Cairo) |
|
Phase 2 Clinical |
New York Medical College |
Leukemia; Anemia; Thalassemia; Hodgkin Disease; Anemia, Aplastic; Thrombocytopenia; Lymphoma, Non-Hodgkin; Kostmann Syndrome; Anemia, Sickle Cell |
Details
|
| MK-6070 |
HPN-328; MK-6070 |
Phase 2 Clinical |
Harpoon Therapeutics |
Small Cell Lung Carcinoma |
Details
|
| Cibisatamab |
CEA-TCB; RG-7802; RO-6958688; CEA-CD3 TCB |
Phase 2 Clinical |
F. Hoffmann-La Roche Ltd |
Solid tumours; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| CD3/CD19 neg allogeneic BMT (National Institute of Allergy and Infectious Diseases/University of Pittsburgh) |
|
Phase 2 Clinical |
National Institute Of Allergy And Infectious Diseases (Niaid), University Of Pittsburgh |
Primary Immunodeficiency Diseases; Female Urogenital Diseases; Inflammation |
Details
|
| HPN-536 |
HPN-536 |
Phase 2 Clinical |
Harpoon Therapeutics |
Neoplasms |
Details
|
| MBS-303 |
MBS-303 |
Phase 2 Clinical |
Beijing Mabworks Biotech Co Ltd |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
| HBM-7022 |
HBM-7022; AZD-5863 |
Phase 2 Clinical |
Harbour Biomed |
Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Neoplasms; Digestive System Neoplasms; Esophageal adenocarcinoma; Carcinoma, Pancreatic Ductal; Gastrointestinal Neoplasms |
Details
|
| TAK-280 |
MVC-280; TAK-280 |
Phase 2 Clinical |
Maverick Therapeutics Inc |
Solid tumours; Neoplasms; Neoplasm Metastasis |
Details
|
| GB-261 |
GB-261 |
Phase 2 Clinical |
Genor Biopharma Co Ltd |
Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| REGN-5459 |
REGN-5459 |
Phase 2 Clinical |
Regeneron Pharmaceuticals Inc |
Multiple Myeloma; Renal Insufficiency, Chronic |
Details
|
| IBI-3003 |
IBI3003; IBI-3003 |
Phase 2 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Multiple Myeloma |
Details
|
| MBS-314 |
MBS-314 |
Phase 2 Clinical |
Beijing Mabworks Biotech Co Ltd |
Multiple Myeloma |
Details
|
| RO7515629 |
RO7515629; RO-7515629; RG-6353 |
Phase 2 Clinical |
F. Hoffmann-La Roche Ag |
Ovarian Neoplasms; Carcinoma, Renal Cell; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| BI-764532 |
BI-764532; OBT620 |
Phase 2 Clinical |
C.H. Boehringer Sohn Ag & Co. Kg |
Small Cell Lung Carcinoma; Neoplasms; Neuroendocrine Tumors; Carcinoma, Neuroendocrine; Glioma |
Details
|
| GEN3017 |
GEN-3017 |
Phase 2 Clinical |
Genmab A/S |
Hematologic Neoplasms; Hodgkin Disease; Lymphoma, Non-Hodgkin |
Details
|
| MP0533 |
MP0533 |
Phase 2 Clinical |
Molecular Partners Ag |
Leukemia, Myeloid, Acute |
Details
|
| CD30 biAb-AATC(The Medical College Of Wisconsin Nonprofit) |
|
Phase 2 Clinical |
The Medical College Of Wisconsin Nonprofit |
Lymphoma, B-Cell; Leukemia; Hodgkin Disease; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous |
Details
|
| APVO-436 |
APVO-436; APVO436 |
Phase 2 Clinical |
Aptevo |
Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
Details
|
| Emfizatamab |
GNC-038 |
Phase 2 Clinical |
Sichuan Baili Pharmaceutical Co Ltd, SystImmune |
Solid tumours; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Central Nervous System Lymphoma |
Details
|
| GEN-1047 |
GEN-1047 |
Phase 2 Clinical |
Genmab A/S |
Carcinoma, Non-Small-Cell Lung |
Details
|
| REGN-4336 |
REGN-4336 |
Phase 2 Clinical |
Regeneron Pharmaceuticals Inc |
Prostatic Neoplasms, Castration-Resistant |
Details
|
| CM-350 |
CM-350 |
Phase 2 Clinical |
Keymed Biosciences Co Ltd |
Solid tumours |
Details
|
| 1-A-46 |
BR-110; 1A46; 1-A-46; CMG1A46; CMG1A-46; BR110 |
Phase 2 Clinical |
Chengdu Chimagen Biosciences Co Ltd, Hisun Biopharmaceutical Co Ltd, BioRay Pharmaceutical Co Ltd |
Lymphoma, B-Cell; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
| LBL-034 |
LBL-034 |
Phase 2 Clinical |
Nanjing Leads Biolabs Co Ltd |
Neoplasms; Multiple Myeloma |
Details
|
| LBL-033 |
LBL-033 |
Phase 2 Clinical |
Nanjing Leads Biolabs Co Ltd |
Neoplasms |
Details
|
| CM-336(Connaught Biomedical Technology) |
CM-336 |
Phase 2 Clinical |
Keymed Biosciences Co Ltd |
Multiple Myeloma |
Details
|
| ICP-B02 |
CM-355; ICP-B02 |
Phase 2 Clinical |
Beijing Tiannuo Jiancheng Pharmaceutical Technology Co Ltd, Keymed Biosciences Co Ltd |
Hematologic Neoplasms; Hematoma; Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
| SMET-12 |
SMET-12 |
Phase 2 Clinical |
Zhejiang Shimai Pharmaceutical Co Ltd |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
| QLS-31905 |
QLS-31905 |
Phase 2 Clinical |
Qilu Pharmaceutical Co Ltd |
Solid tumours; Neoplasms |
Details
|
| Nebratamig |
GNC-035 |
Phase 2 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Solid tumours; Hematologic Neoplasms; Breast Neoplasms; Metastatic breast cancer; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| TAK-186 |
EGFR x CD3 COBRA; MVC-101; TAK-186 |
Phase 2 Clinical |
Takeda Pharmaceutical Co Ltd |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| EMB-06 |
EMB-06; EMB06 |
Phase 2 Clinical |
Shanghai Epimab Biotherapeutics, Inc |
Multiple Myeloma |
Details
|
| AZD-0486 |
TNB-486; AZD-0486; AZD0486 |
Phase 2 Clinical |
Teneobio Inc |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin |
Details
|
| BNT-142 |
BNT-142 |
Phase 2 Clinical |
Biontech Se |
Solid tumours |
Details
|
| CN-201 |
CN-201 |
Phase 2 Clinical |
Curon Biopharmaceutical Ltd |
Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
| ZG006 |
ZG006; ZG-006 |
Phase 2 Clinical |
Gensun Biopharma Inc, Suzhou Zelgen Biopharmaceuticals Co Ltd |
Solid tumours; Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Neuroendocrine |
Details
|
| EX-103 |
EX-103; EX103 |
Phase 2 Clinical |
Guangzhou Excelmab Inc |
Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| Anti-CD3 monoclonal antibody (Jinan Tiankang Biological Products) |
|
Phase 2 Clinical |
Jinan Tiankang Biological Products Co Ltd |
Anemia, Aplastic |
Details
|
| Cevostamab |
RG-6160; BFCR-4350A; RO-7187797 |
Phase 2 Clinical |
Genentech Inc |
Multiple Myeloma |
Details
|
| Anti-CD3/anti-EGFR -activated T cells (Barbara Ann Karmanos Cancer Institute) |
|
Phase 2 Clinical |
Barbara Ann Karmanos Cancer Institute, University Of Virginia |
Glioblastoma; Pancreatic Neoplasms |
Details
|
| Ubamatamab |
REGN-4018 |
Phase 2 Clinical |
Regeneron Pharmaceuticals Inc |
Ovarian Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms |
Details
|
| Anti-CD3-anti-HER2-activated T cells |
|
Phase 2 Clinical |
Transtarget |
Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Prostatic Neoplasms |
Details
|
| JCAR-014 |
JCAR-014; JCAR021 |
Phase 2 Clinical |
Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute, Juno Therapeutics Inc |
Lymphoma, B-Cell; Leukemia; Leukemia, Lymphoid; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Candidiasis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| A-319 |
A-319 |
Phase 1 Clinical |
Evive Biotech Ltd |
Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell |
Details
|
| BCMA TriTAC |
HPN-217 |
Phase 1 Clinical |
Harpoon Therapeutics, Abbvie Inc |
Multiple Myeloma |
Details
|
| Membrane bound ligand T-SIGn virus |
NG-348 |
Phase 1 Clinical |
Akamis Bio Ltd |
Neoplasms |
Details
|
| NG-641 |
EnAd-FAP-BiTE; EnAd-FAP-Tac; NG-641; NG-aFAP |
Phase 1 Clinical |
Akamis Bio Ltd, University Of Oxford |
Squamous Cell Carcinoma of Head and Neck; Neoplasms, Glandular and Epithelial; Neoplasm Metastasis |
Details
|
| Vixtimotamab |
T-564; AMV-564 |
Phase 1 Clinical |
Amphivena Therapeutics Inc |
Solid tumours; Myelodysplastic Syndromes |
Details
|
| MGD-014 |
MGD-014 |
Phase 1 Clinical |
Macrogenics Inc |
HIV Infections |
Details
|
| JNJ-63898081 |
JNJ-8081; JNJ-63898081 |
Phase 1 Clinical |
Johnson & Johnson Innovative Medicine |
Neoplasms |
Details
|
| K-193 |
K-193 |
Phase 1 Clinical |
Beijing Lvzhu Biological Technology Co Ltd |
Lymphoma, B-Cell |
Details
|
| Anti-EGFR-bispecific antibody armed activated T-cell therapy (Memorial Sloan Kettering Cancer Center) |
|
Phase 1 Clinical |
Memorial Sloan Kettering Cancer Center |
Pancreatic Neoplasms |
Details
|
| Runimotamab |
BTRC-4017A; RG-6194; RO-7227780 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Solid tumours; Neoplasms |
Details
|
| Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center |
|
Phase 1 Clinical |
Roger Williams Medical Center |
Prostatic Neoplasms |
Details
|
| ONO-4685 |
ONO-4685 |
Phase 1 Clinical |
Merus Nv |
Psoriasis; Lymphoma, T-Cell; Plaque psoriasis |
Details
|
| WVT-078(Novartis Pharma) |
WVT-078 |
Phase 1 Clinical |
Novartis Pharma Ag |
Multiple Myeloma |
Details
|
| M-802(Wuhan Yzy Biopharma/CSPC Pharmaceutical) |
M-802 |
Phase 1 Clinical |
Wuhan Yzy Biopharma Co Ltd, CSPC Pharmaceutical Group Ltd |
Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Breast Neoplasms |
Details
|
| Emirodatamab |
AMG-427 |
Phase 1 Clinical |
Amgen Inc |
Leukemia, Myeloid, Acute |
Details
|
| JNJ-63709178 |
JNJ-9178; CNTO-9958; JNJ-63709178 |
Phase 1 Clinical |
Johnson & Johnson Innovative Medicine, Genmab A/S |
Leukemia, Myeloid, Acute |
Details
|
| SAR-442257 |
SAR-442257 |
Phase 1 Clinical |
Sanofi |
Neoplasms |
Details
|
| CC-1 |
CC-1 |
Phase 1 Clinical |
University Of Tubingen, German Cancer Research Center (Dkfz) |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Carcinoma, Squamous Cell |
Details
|
| Acapatamab |
AMG-160 |
Phase 1 Clinical |
Amgen Inc |
Prostatic Neoplasms, Castration-Resistant; Carcinoma, Non-Small-Cell Lung |
Details
|
| Pavurutamab |
AMG-701 |
Phase 1 Clinical |
Amgen Inc |
Multiple Myeloma |
Details
|
| Xaluritamig |
AMG-509 |
Phase 1 Clinical |
Xencor Inc, Amgen Inc |
Prostatic Neoplasms, Castration-Resistant |
Details
|
| CC-3 |
CC-3 |
Phase 1 Clinical |
Eberhard Karls University Of Tubingen, Germany |
Colorectal Neoplasms; Gastrointestinal Neoplasms |
Details
|
| JS-203 |
JS-203 |
Phase 1 Clinical |
Shanghai Junshi Biological Engineering Co Ltd |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
| BC-004 |
BC-004 |
Phase 1 Clinical |
Shandong Buchang Pharmaceuticals Co Ltd |
Solid tumours; Breast Neoplasms |
Details
|
| JY-016 |
JY-016 |
Phase 1 Clinical |
Beijing Jingyitaixiang Technology Development Co Ltd, Beijing Eastern Biotech Co Ltd |
Solid tumours; Colorectal Neoplasms; Lung Neoplasms |
Details
|
| EX-105 |
EX-105; EX105 |
Phase 1 Clinical |
Guangzhou Excelmab Inc |
Solid tumours |
Details
|
| EMB-07 |
EMB-07 |
Phase 1 Clinical |
Shanghai Epimab Biotherapeutics, Inc |
Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Adenocarcinoma of Lung; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Lymphoma; Uterine Neoplasms; Neoplasm Metastasis |
Details
|
| BA-3182 |
BA-3182 |
Phase 1 Clinical |
Bioatla |
Solid tumours; Adenocarcinoma |
Details
|
| BA-1202 |
BA-1202 |
Phase 1 Clinical |
Shandong Boan Biotechnology Co Ltd |
Solid tumours |
Details
|
| CLN-978 |
CLN-978 |
Phase 1 Clinical |
Adimab LLC |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
| MGD-024 |
MGD-024 |
Phase 1 Clinical |
Macrogenics Inc |
Leukemia, Myelogenous, Chronic; Leukemia, Hairy Cell; Hodgkin Disease; Myelodysplastic Syndromes; Neoplasms; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, B-Cell; Leukemia, Myeloid, Acute |
Details
|
| ARB-202 |
ARB-202 |
Phase 1 Clinical |
Arbele Corp |
Liver Neoplasms; Biliary Tract Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal adenocarcinoma; Gastrointestinal Neoplasms |
Details
|
| CX-904 |
CX-904 |
Phase 1 Clinical |
Amgen Inc, Cytomx Therapeutics Inc |
Solid tumours; Neoplasms |
Details
|
| CLN-049 |
CLN-049 |
Phase 1 Clinical |
University Of Tubingen, German Cancer Research Center (Dkfz) |
Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
Details
|
| XmAb-819 |
XmAb-819 |
Phase 1 Clinical |
Xencor Inc |
Kidney Neoplasms; Carcinoma, Renal Cell |
Details
|
| JNJ-70218902 |
JNJ-70218902 |
Phase 1 Clinical |
Johnson & Johnson Innovative Medicine |
Neoplasms |
Details
|
| JNJ-67571244 |
JNJ-67571244; JNJ-67371244; JNJ-1244 |
Phase 1 Clinical |
Johnson & Johnson |
Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
Details
|
| SCTB-35 |
SCTB35; SCTB-35 |
Phase 1 Clinical |
SinoCelltech Ltd |
Lymphoma, B-Cell |
Details
|
| JNJ-87890387 |
JNJ-87890387 |
Phase 1 Clinical |
Janssen Research & Development Llc |
Solid tumours |
Details
|
| XmAb-541 |
XmAb541; XmAb-541 |
Phase 1 Clinical |
Xencor Inc |
Ovarian Neoplasms; Ovarian germ cell tumor; Germinoma; Endometrial Neoplasms; Neoplasms, Germ Cell and Embryonal |
Details
|
| [89Zr]Zr-BI-764532 |
|
Phase 1 Clinical |
C.H. Boehringer Sohn Ag & Co. Kg, Boehringer Ingelheim Gmbh |
Small Cell Lung Carcinoma; Carcinoma, Neuroendocrine |
Details
|
| TGI-6 |
TGI-6 |
Phase 1 Clinical |
Hefei TG ImmunoPharma Co Ltd |
Solid tumours; Colorectal Neoplasms |
Details
|
| SIM-0500 |
SIM-0500; SIM0500 |
Phase 1 Clinical |
Hainan Xiansheng Re Ming Pharmaceutical Co Ltd |
Bone Marrow Neoplasms; Multiple Myeloma |
Details
|
| Recombinant anti BCMA/CD3 bispecific antibody(Hualan Genetic Engineering) |
|
Phase 1 Clinical |
Hualan Genetic Engineering (Henan) Co Ltd |
Multiple Myeloma |
Details
|
| Oncolytic Virus R130（Yunying Medical） |
R-130-OV; R130; R-130 |
Phase 1 Clinical |
Shanghai Yunying Medical Technology Co Ltd |
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Melanoma; Laryngeal Neoplasms; Pharyngeal Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Bone Neoplasms; Peritoneal Neoplasms; Sarcoma; Osteosarcoma; Head and Neck Neoplasms; Brain Neoplasms; Otorhinolaryngologic Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Nose Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma; Carcinoma, Bronchogenic; Liver Neoplasms; Ovarian Neoplasms; Kidney Neoplasms |
Details
|
| ASP2074 |
ASP-2074; ASP2074 |
Phase 1 Clinical |
Astellas Pharma Global Development Inc |
Solid tumours |
Details
|
| OBT620 |
OBT620 |
Phase 1 Clinical |
Boehringer Ingelheim Gmbh, Oxford Biotherapeutics Ltd |
Small Cell Lung Carcinoma |
Details
|
| CBA-1535 |
CBA-1535 |
Phase 1 Clinical |
Chiome Bioscience Inc |
Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Mesothelioma; Carcinoma, Non-Small-Cell Lung |
Details
|
| JANX-008 |
EGFR-TRACTr; JANX008; JANX-008 |
Phase 1 Clinical |
Janux Therapeutics Inc |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| JANX-007 |
JANX-007; PSMA-TRACTr |
Phase 1 Clinical |
Janux Therapeutics Inc |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
| TQB-2934 |
TQB2934; TQB-2934 |
Phase 1 Clinical |
Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group |
Multiple Myeloma |
Details
|
| JNJ-80948543 |
JNJ-80948543 |
Phase 1 Clinical |
Janssen Research & Development Llc |
Lymphoma, B-Cell; Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| PIT-565 |
PIT-565 |
Phase 1 Clinical |
Novartis Pharma Ag |
Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lupus Erythematosus, Systemic; Leukemia, Myeloid, Acute |
Details
|
| CC-312 |
CC-312 |
Phase 1 Clinical |
CytoCares (Shanghai) Inc |
Hematologic Neoplasms; Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| ASP-2138 |
ASP-2138 |
Phase 1 Clinical |
Astellas Pharma Global Development Inc, Xencor Inc |
Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms |
Details
|
| ISB-2001 |
ISB-2001 |
Phase 1 Clinical |
Ichnos Sciences Sa |
Multiple Myeloma |
Details
|
| GR-1901 |
GR1901; GR-1901 |
Phase 1 Clinical |
Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd |
Leukemia, Myeloid, Acute |
Details
|
| AMG-794 |
AMG-794 |
Phase 1 Clinical |
Amgen Inc |
Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung |
Details
|
| QLS-31904 |
QLS31904; QLS-31904 |
Phase 1 Clinical |
Qilu Pharmaceutical Co Ltd |
Solid tumours |
Details
|
| YK-012 |
YK012 |
Phase 1 Clinical |
Yikesite (Beijing) Pharmaceutical Technology Development Co Ltd |
Lymphoma, B-Cell |
Details
|
| RO-7428731 |
RO-7428731; RG-6156 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Glioblastoma |
Details
|
| GBR-1342 |
GBR-1342; ISB-1342 |
Phase 1 Clinical |
Glenmark Pharmaceuticals Ltd |
Multiple Myeloma |
Details
|
| Recombinant humanized anti-CD19/CD3 bispecific antibody(New Time Pharmaceutical) |
LNF-1904 |
Phase 1 Clinical |
Shandong New Time Pharmaceutical Co Ltd |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
| XmAb-968 |
XmAb968 |
Phase 1 Clinical |
Xencor Inc |
Hematologic Neoplasms; Leukemia, Promyelocytic, Acute |
Details
|
| GR-1803 |
GR-1803 |
Phase 1 Clinical |
Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
| XmAb-18968 |
XmAb-18968 |
Phase 1 Clinical |
The Medical College Of Wisconsin Nonprofit |
Leukemia, Myeloid, Acute |
Details
|
| SQZ-622(Novartis Pharma) |
SQZ-622 |
Phase 1 Clinical |
Novartis Pharma Ag |
Leukemia, Myeloid, Acute |
Details
|
| Forimtamig |
RG-6234 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Multiple Myeloma |
Details
|
| RG-6232 |
RG-6232 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Melanoma |
Details
|
| RG-6007 |
RO-7283420; RG-6007 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Leukemia, Myeloid, Acute |
Details
|
| SAR-443216 |
SAR-443216 |
Phase 1 Clinical |
Sanofi |
Solid tumours; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Lung Neoplasms |
Details
|
| Recombinant oncolytic type II herpes simplex virus (Binhui Biopharmaceutical) |
BS-006; oHSV2-BiTEs |
Phase 1 Clinical |
Wuhan Binhui Biotechnology Co Ltd |
Solid tumours; Neoplasms; Melanoma; Uterine Cervical Neoplasms |
Details
|
| JNJ-78306358 |
JNJ-78306358; JNJ-6358 |
Phase 1 Clinical |
Janssen Research & Development Llc |
Solid tumours |
Details
|
| F-182112 |
F-182112; F182112 |
Phase 1 Clinical |
Shandong New Time Pharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
| TNB-585 |
TNB-585; AMG-340 |
Phase 1 Clinical |
Teneobio Inc |
Prostatic Neoplasms, Castration-Resistant |
Details
|
| BC-3448 |
BC3448; BC-3448 |
Phase 1 Clinical |
|
Solid tumours |
Details
|
| IBI-389 |
IBI-389 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Neoplasms |
Details
|
| hEGFRvIII-CD3 Bi-scFv |
|
Phase 1 Clinical |
Duke University |
Glioblastoma; Glioma |
Details
|
| JNJ-78278343 |
|
Phase 1 Clinical |
Janssen Research & Development Llc |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
| TQB-2825 |
TQB-2825 |
Phase 1 Clinical |
Wuxi Biologics Co Ltd |
Hematologic Neoplasms |
Details
|
| RGV-004 |
RGV-004 |
Phase 1 Clinical |
Hangzhou Rongu Biotechnology Co Ltd |
Lymphoma, B-Cell |
Details
|
| Recombinant humanized anti-BCMA/CD3 bispecific antibody(New Time Pharmaceutical) |
|
Phase 1 Clinical |
Shandong New Time Pharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
| NVG-111 |
NVG-111 |
Phase 1 Clinical |
NovalGen Ltd |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Melanoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| BI-765049 |
BI-765049; OBT-624 |
Phase 1 Clinical |
Oxford Biotherapeutics Ltd |
Solid tumours |
Details
|
| GNC-039 |
GNC-039 |
Phase 1 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis |
Details
|
| RO-7425781 |
RO-7425781 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Multiple Myeloma |
Details
|
| RO-7293583 |
RO-7293583 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Skin Melanoma; Uveal melanoma; Melanoma |
Details
|
| Rezetamig |
JNJ-8780; JNJ75348780; JNJ-75348780 |
Phase 1 Clinical |
Teneobio Inc |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| Y-150(Wuhan Yzy Biopharma/CSPC Pharmaceutical) |
Y-150; Y150 |
Phase 1 Clinical |
Wuhan Yzy Biopharma Co Ltd, CSPC Pharmaceutical Group Ltd |
Multiple Myeloma |
Details
|
| EX-101 |
EX-101; EX101 |
Phase 1 Clinical |
Guangzhou Excelmab Inc |
Solid tumours |
Details
|
| Plamotamab |
XmAb-13676 |
Phase 1 Clinical |
Xencor Inc |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| A-337 |
A-337 |
Phase 1 Clinical |
Evive Biotech Ltd |
Solid tumours; Neoplasms |
Details
|
| CCW-702 |
CCW-702 |
Phase 1 Clinical |
The Scripps Research Institute Inc, Abbvie Inc |
Prostatic Neoplasms |
Details
|
| Tepoditamab |
MCLA-117 |
Phase 1 Clinical |
Pharmaceutical Research Associates, Institute Gustave-Roussy, Merus Nv, Vu University Medical Center, Lgc |
Leukemia, Myeloid, Acute |
Details
|
| ERY-974 |
ERY-974 |
Phase 1 Clinical |
Chugai Pharmaceutical Co Ltd |
Solid tumours; Carcinoma, Hepatocellular |
Details
|
| InHeAb-01 |
InHeAb-01; bsAB |
Clinical |
University Hospital Tuebingen |
Neoplasms |
Details
|
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one. 
A-Z
